Granata Bio is a Boston-based biopharmaceutical company building a portfolio of fertility and reproductive-health therapies. Founded in 2018, it in-licenses and develops medications used in IVF outside the US, runs its own clinical programs, and is expanding into ovarian biology. Its lead asset is an investigational human menopausal gonadotropin in the pivotal Phase III GRACE study, and its 2025 acquisition of Oviva Therapeutics added a first-in-class therapeutic aimed at extending ovarian function. The company targets the multi-billion-dollar global infertility medication market with the goal of expanding patient access and improving IVF outcomes.
Evan Sussman is the co-founder and CEO of Granata Bio, a Boston-based biopharma company expanding access to fertility care by in-licensing IVF medications proven abroad and bringing them through U.S. clinical development and commercialization. A former fertility business unit head at EMD Serono, he built Granata to be revenue-positive early through a fee-for-service model, then raised a $14M Series A led by GV (Google Ventures), extended it, acquired ovarian-aging biotech Oviva Therapeutics, and struck a strategic investment and co-development deal with Gedeon Richter.